Market Closed -
Australian S.E.
02:10:53 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
280.1
AUD
|
+0.64%
|
|
-0.29%
|
-2.29%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
68,373
|
89,914
|
97,314
|
89,378
|
89,111
|
89,874
|
-
|
-
|
Enterprise Value (EV)
1 |
72,378
|
94,712
|
101,308
|
88,599
|
99,790
|
99,690
|
98,525
|
97,031
|
P/E ratio
|
35.7
x
|
42.9
x
|
41
x
|
38.7
x
|
40.8
x
|
32.9
x
|
27.4
x
|
23.5
x
|
Yield
|
1.23%
|
1.02%
|
1.04%
|
1.2%
|
1.28%
|
1.43%
|
1.66%
|
1.91%
|
Capitalization / Revenue
|
8.01
x
|
9.83
x
|
9.44
x
|
8.46
x
|
6.7
x
|
6.11
x
|
5.64
x
|
5.25
x
|
EV / Revenue
|
8.48
x
|
10.4
x
|
9.83
x
|
8.39
x
|
7.5
x
|
6.77
x
|
6.18
x
|
5.67
x
|
EV / EBITDA
|
25.1
x
|
30.2
x
|
27.2
x
|
24.6
x
|
25.6
x
|
20.3
x
|
18
x
|
15.6
x
|
EV / FCF
|
137
x
|
73.9
x
|
41.8
x
|
57.2
x
|
72.7
x
|
45.2
x
|
33.9
x
|
26.9
x
|
FCF Yield
|
0.73%
|
1.35%
|
2.39%
|
1.75%
|
1.38%
|
2.21%
|
2.95%
|
3.72%
|
Price to Book
|
13
x
|
13.8
x
|
11.6
x
|
6.13
x
|
5.64
x
|
5.02
x
|
4.54
x
|
4.08
x
|
Nbr of stocks (in thousands)
|
453,139
|
454,049
|
455,126
|
481,706
|
482,372
|
483,253
|
-
|
-
|
Reference price
2 |
150.9
|
198.0
|
213.8
|
185.5
|
184.7
|
186.0
|
186.0
|
186.0
|
Announcement Date
|
8/13/19
|
8/18/20
|
8/17/21
|
8/16/22
|
8/14/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8,539
|
9,151
|
10,310
|
10,562
|
13,310
|
14,717
|
15,933
|
17,114
|
EBITDA
1 |
2,879
|
3,136
|
3,720
|
3,596
|
3,900
|
4,905
|
5,483
|
6,207
|
EBIT
1 |
2,504
|
2,716
|
3,130
|
2,927
|
3,069
|
4,198
|
4,757
|
5,458
|
Operating Margin
|
29.33%
|
29.69%
|
30.36%
|
27.72%
|
23.06%
|
28.52%
|
29.86%
|
31.89%
|
Earnings before Tax (EBT)
1 |
2,341
|
2,573
|
2,963
|
2,780
|
2,663
|
3,642
|
4,285
|
4,957
|
Net income
1 |
1,919
|
2,102
|
2,375
|
2,255
|
2,194
|
2,711
|
3,259
|
3,790
|
Net margin
|
22.47%
|
22.98%
|
23.04%
|
21.35%
|
16.48%
|
18.42%
|
20.45%
|
22.15%
|
EPS
2 |
4.226
|
4.615
|
5.210
|
4.800
|
4.530
|
5.653
|
6.787
|
7.914
|
Free Cash Flow
1 |
526.8
|
1,282
|
2,426
|
1,550
|
1,373
|
2,205
|
2,907
|
3,608
|
FCF margin
|
6.17%
|
14%
|
23.53%
|
14.67%
|
10.32%
|
14.98%
|
18.25%
|
21.08%
|
FCF Conversion (EBITDA)
|
18.3%
|
40.86%
|
65.21%
|
43.1%
|
35.21%
|
44.95%
|
53.02%
|
58.13%
|
FCF Conversion (Net income)
|
27.46%
|
60.95%
|
102.13%
|
68.74%
|
62.58%
|
81.33%
|
89.22%
|
95.2%
|
Dividend per Share
2 |
1.850
|
2.020
|
2.220
|
2.220
|
2.360
|
2.653
|
3.086
|
3.555
|
Announcement Date
|
8/13/19
|
8/18/20
|
8/17/21
|
8/16/22
|
8/14/23
|
-
|
-
|
-
|
Fiscal Period: June |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
4,911
|
4,240
|
5,739
|
4,571
|
6,041
|
4,521
|
7,184
|
6,126
|
8,053
|
6,574
|
8,662
|
7,234
|
EBITDA
1 |
1,836
|
1,300
|
2,638
|
1,081
|
2,479
|
1,117
|
2,516
|
1,384
|
3,042
|
2,146
|
-
|
-
|
EBIT
1 |
1,632
|
1,084
|
2,358
|
772
|
2,215
|
712.7
|
2,134
|
934.7
|
2,795
|
1,524
|
2,962
|
1,646
|
Operating Margin
|
33.23%
|
25.58%
|
41.09%
|
16.89%
|
36.67%
|
15.77%
|
29.71%
|
15.26%
|
34.71%
|
23.17%
|
34.2%
|
22.75%
|
Earnings before Tax (EBT)
|
1,561
|
1,011
|
2,251
|
712.1
|
2,145
|
635.2
|
1,963
|
-
|
2,379
|
-
|
-
|
-
|
Net income
1 |
1,248
|
854.5
|
1,810
|
565
|
1,760
|
494.4
|
1,623
|
570.8
|
1,901
|
759.5
|
2,061
|
970
|
Net margin
|
25.41%
|
20.15%
|
31.54%
|
12.36%
|
29.13%
|
10.94%
|
22.6%
|
9.32%
|
23.61%
|
11.55%
|
23.79%
|
13.41%
|
EPS
|
2.740
|
1.875
|
3.980
|
1.230
|
3.850
|
0.9600
|
3.370
|
-
|
3.920
|
-
|
-
|
-
|
Dividend per Share
2 |
0.9500
|
1.070
|
1.040
|
1.180
|
1.040
|
1.180
|
1.070
|
1.290
|
1.190
|
1.325
|
1.280
|
1.560
|
Announcement Date
|
2/11/20
|
8/18/20
|
2/17/21
|
8/17/21
|
2/15/22
|
8/16/22
|
2/13/23
|
8/14/23
|
2/12/24
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
4,005
|
4,798
|
3,993
|
-
|
10,679
|
9,816
|
8,651
|
7,157
|
Net Cash position
1 |
-
|
-
|
-
|
779
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.391
x
|
1.53
x
|
1.074
x
|
-
|
2.738
x
|
2.001
x
|
1.578
x
|
1.153
x
|
Free Cash Flow
1 |
527
|
1,282
|
2,426
|
1,550
|
1,373
|
2,205
|
2,907
|
3,608
|
ROE (net income / shareholders' equity)
|
41.1%
|
35.7%
|
31.9%
|
19.6%
|
14.5%
|
17.3%
|
18%
|
19%
|
ROA (Net income/ Total Assets)
|
16.6%
|
15.1%
|
14.1%
|
9.7%
|
6.79%
|
8.99%
|
9.85%
|
10.8%
|
Assets
1 |
11,544
|
13,890
|
16,886
|
23,252
|
32,290
|
30,159
|
33,074
|
35,024
|
Book Value Per Share
2 |
11.60
|
14.40
|
18.40
|
30.30
|
32.70
|
37.10
|
41.00
|
45.60
|
Cash Flow per Share
2 |
3.620
|
5.460
|
7.940
|
5.590
|
5.380
|
5.940
|
7.850
|
9.680
|
Capex
1 |
1,118
|
1,207
|
1,196
|
1,079
|
1,228
|
876
|
980
|
1,026
|
Capex / Sales
|
13.09%
|
13.19%
|
11.6%
|
10.21%
|
9.23%
|
5.95%
|
6.15%
|
5.99%
|
Announcement Date
|
8/13/19
|
8/18/20
|
8/17/21
|
8/16/22
|
8/14/23
|
-
|
-
|
-
|
Average target price
202.7
USD Spread / Average Target +8.98% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.29% | 89.87B | | -3.95% | 37.57B | | -13.07% | 32.75B | | +63.05% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +5.77% | 9.11B | | -17.66% | 7.32B |
Biopharmaceuticals
|